CA3121910A1 - Inhibitors of apol1 and methods of using same - Google Patents

Inhibitors of apol1 and methods of using same Download PDF

Info

Publication number
CA3121910A1
CA3121910A1 CA3121910A CA3121910A CA3121910A1 CA 3121910 A1 CA3121910 A1 CA 3121910A1 CA 3121910 A CA3121910 A CA 3121910A CA 3121910 A CA3121910 A CA 3121910A CA 3121910 A1 CA3121910 A1 CA 3121910A1
Authority
CA
Canada
Prior art keywords
ppm
groups
compound
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121910A
Other languages
English (en)
French (fr)
Inventor
Michael Brodney
Kevin Gagnon
Kan-Nian Hu
Ales Medek
Peter Rose
Yi Shi
Muna SHRESTHA
Faith WITKOS
Jingrong Cao
Jon H. Come
Leslie A. DAKIN
Francois Denis
Warren A. DORSCH
Anne FORTIER
Martine Hamel
Elaine B. Krueger
Brian Ledford
Suganthini S. Nanthakumar
Olivier Nicolas
Camil SAYEGH
Timothy J. SENTER
Tiansheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CA3121910A1 publication Critical patent/CA3121910A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA3121910A 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same Pending CA3121910A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
US62/780,667 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CA3121910A1 true CA3121910A1 (en) 2020-06-25

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121910A Pending CA3121910A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Country Status (26)

Country Link
US (3) US11618746B2 (https=)
EP (1) EP3897833B1 (https=)
JP (1) JP7573528B2 (https=)
KR (2) KR102912203B1 (https=)
CN (1) CN113453760B (https=)
AR (1) AR116913A1 (https=)
AU (1) AU2019405477B2 (https=)
CA (1) CA3121910A1 (https=)
CL (1) CL2021001561A1 (https=)
CO (1) CO2021009053A2 (https=)
CR (1) CR20210383A (https=)
DK (1) DK3897833T3 (https=)
DO (1) DOP2021000116A (https=)
EC (1) ECSP21052184A (https=)
FI (1) FI3897833T3 (https=)
IL (2) IL283592B2 (https=)
JO (3) JOP20210131A1 (https=)
MA (1) MA54538A (https=)
MX (1) MX2021007152A (https=)
PE (1) PE20212302A1 (https=)
SA (1) SA521422270B1 (https=)
SG (1) SG11202105769XA (https=)
TW (1) TWI848031B (https=)
UA (1) UA128375C2 (https=)
UY (1) UY38514A (https=)
WO (1) WO2020131807A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
WO2021154997A1 (en) * 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3173808A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CA3185604A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
WO2021252849A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
WO2021252863A1 (en) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) * 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN116997546A (zh) * 2021-02-19 2023-11-03 梅兹治疗公司 Apol1抑制剂及使用方法
MX2024002229A (es) * 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
CA3240523A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
IL314330A (en) 2022-01-18 2024-09-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
US20260055083A1 (en) * 2022-08-19 2026-02-26 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
WO2026012338A1 (zh) * 2024-07-09 2026-01-15 上海旭成医药科技有限公司 一种APOLs抑制剂

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
EP0934941A1 (en) 1996-08-09 1999-08-11 Eisai Co., Ltd. Benzopiperidine derivatives
DE69814012T2 (de) 1997-12-19 2004-04-01 Eli Lilly And Co., Indianapolis Hypoglykàmische imidazoline derivate
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
AU2003237593A1 (en) * 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
CA2537349A1 (en) 2003-09-03 2005-03-10 Galapagos Nv The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AU2006316321A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
WO2008092231A1 (en) * 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CN101801965B (zh) 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
EP2435407B1 (en) 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
ES2436241T3 (es) 2009-11-16 2013-12-27 Eli Lilly And Company Compuestos de espiropiperidina como antagonistas de receptor oral-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
JP2016531874A (ja) * 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
JP2017536342A (ja) 2014-10-08 2017-12-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物
TW201632522A (zh) 2014-11-21 2016-09-16 伊史帝夫博士實驗室股份有限公司 針對疼痛具有多模式活性的螺－異喹啉－１，４’－哌啶化合物
ES2865199T3 (es) 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
JP6990657B2 (ja) 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
MA53924A (fr) 2018-05-22 2021-08-25 Ionis Pharmaceuticals Inc Modulateurs de l'expression d'apol1
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
TW202136219A (zh) 2019-12-19 2021-10-01 美商卡司馬療法公司 Trpml調節劑
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3173808A1 (en) * 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
AU2021259580A1 (en) 2020-04-22 2022-11-24 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
WO2021224927A1 (en) 2020-05-07 2021-11-11 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
WO2021252849A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
MX2024002229A (es) 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
CA3240523A1 (en) 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
JP2025505645A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Also Published As

Publication number Publication date
IL283592A (en) 2021-07-29
US20230271945A1 (en) 2023-08-31
US12060346B2 (en) 2024-08-13
JOP20210129A1 (ar) 2023-01-30
US20250042878A1 (en) 2025-02-06
ECSP21052184A (es) 2021-08-31
AU2019405477A1 (en) 2021-06-24
KR20260020195A (ko) 2026-02-10
AR116913A1 (es) 2021-06-23
US11618746B2 (en) 2023-04-04
SG11202105769XA (en) 2021-07-29
AU2019405477B2 (en) 2025-04-03
UA128375C2 (uk) 2024-06-26
JP2022515369A (ja) 2022-02-18
MA54538A (fr) 2021-10-27
JOP20210130A1 (ar) 2023-01-30
CO2021009053A2 (es) 2021-08-09
CR20210383A (es) 2021-09-22
CN113453760A (zh) 2021-09-28
SA521422270B1 (ar) 2024-02-18
DK3897833T3 (da) 2026-03-30
BR112021011564A2 (pt) 2021-08-31
EP3897833B1 (en) 2026-02-04
TW202039471A (zh) 2020-11-01
CL2021001561A1 (es) 2021-11-26
IL283592B1 (en) 2025-04-01
IL319575A (en) 2025-05-01
KR20210116483A (ko) 2021-09-27
IL283592B2 (en) 2025-08-01
US20200377479A1 (en) 2020-12-03
EP3897833A1 (en) 2021-10-27
JP7573528B2 (ja) 2024-10-25
WO2020131807A1 (en) 2020-06-25
JOP20210131A1 (ar) 2023-01-30
FI3897833T3 (fi) 2026-04-07
KR102912203B1 (ko) 2026-01-16
MX2021007152A (es) 2021-11-03
TWI848031B (zh) 2024-07-11
DOP2021000116A (es) 2021-09-30
UY38514A (es) 2020-07-31
PE20212302A1 (es) 2021-12-10
CN113453760B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
CA3121910A1 (en) Inhibitors of apol1 and methods of using same
CA3185144A1 (en) Inhibitors of apol1 and use of the same
AU2018260844B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
RU2748731C2 (ru) Комбинация, содержащая антагонист ep4 и ингибитор иммунных контрольных точек
CA3168909A1 (en) Inhibitors of apol1 and methods of using same
CA2995997A1 (en) Compounds and compositions useful for treating disorders related to ntrk
KR20210061400A (ko) 유비퀴틴 특이적 펩티다아제 9x의 억제
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
CA3185604A1 (en) Inhibitors of apol1 and use of the same
KR20220163429A (ko) 알파-1-항트립신 결핍증(aatd) 치료를 위한 알파-1-항트립신 조절제로서의 피롤로[2,3-f]인다졸 유도체 및 2,4,5,10-테트라아자트리시클로[7.3.0.03,7]도데카-1,3(7),5,8,11-펜타엔 유도체
CN118632850A (zh) Apol1的螺环抑制剂和其使用方法
CA3178470A1 (en) Modulators of alpha-1 antitrypsin
JP2024540163A (ja) Ｒｘｆｐ１アゴニスト
JP2022510736A (ja) 大環状化合物とその使用
JP2025532510A (ja) アルファ－１アンチトリプシンの調節剤
JP2022511303A (ja) 免疫調節剤、並びにその組成物及び調製方法
CA2374627A1 (en) Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
CA3117113A1 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
BR112021011564B1 (pt) Inibidores de apol1, composições farmacêuticas e uso dos mesmos
EP4417600A1 (en) Shp2 inhibitor, pharmaceutical composition comprising same, and use thereof
TW202543607A (zh) 介白素１７ａ抑制劑及其用途
OA20305A (en) N-substituted-dioxocyclobutenylamino-3hydroxy-picolinamides useful as CCR6 Inhibitors.
HK40049451A (en) Immunomodulator, composition and preparation method thereof
CN107973780A (zh) 一种取代的烯烃类化合物及其制备方法和用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241213

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250306

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250626

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250626